Active Pharmaceutical Ingredient Market to Register Decent CAGR of 6.6% from 2021 to 2028; Biocon Invests USD 100 Million in Novel Production Unit Set to Boost Growth

The global active pharmaceutical ingredient market size was USD 159.35 billion in 2020. The market is projected to grow from USD 174.17 billion in 2021 to USD 272.44 billion in 2028 at a CAGR of 6.6% over 2021-2028. This information is provided by Fortune Business Insights™, in its report, titled, “Active Pharmaceutical Ingredient Market Size, Share & COVID-19 Impact Analysis, By Type (Generic API, and Branded API), By Synthesis (Biological API, and Synthetic API), and Regional Forecast, 2021-2028.”

The market is probable to demonstrate an optimistic viewpoint with the rising trend towards progressions and inventions of therapeutic drugs by numerous pharmaceutical and biotechnology companies.

COVID-19 Impact

Supply Chain Uncertainty to have Hostile Impacts on Global Market

The impact of COVID-19 on this market has been hostile owing to the closure of a number of industrial units in China owing to the COVID-19. Moreover, the absence of raw materials has also resulted in the conclusion of workshops in China.

Also, the decline in demand for pharmaceuticals for definite elective procedures have also resulted in deterioration in the active pharmaceutical ingredient market growth in 2020. Pooled together, these aspects directed to an undesirable effect on the global market.     

SANOFI Launches EUROAPI as name of New Industry Leading European API

Sanofi picks EUROAPI as the name for the imminent leading European company devoted to the expansion, production and advertising of API.

EUROAPI will signify the “made in Europe” API state-of-the-art industrial competences and technologies, with roughly €1 billion in anticipated sales by 2022.

Moreover, addressing current rising medicine scarcities that unfavourably influence patient care, EUROAPI will safeguard supplementary API supply units for Europe and beyond, and aid harmonizing the industry’s huge dependence on API obtained from various regions.

To get a detailed report summary and research scope of this market, click here:

https://www.fortunebusinessinsights.com/active-pharmaceutical-ingredient-api-market-102656

Increasing Incidence of Chronic Disease to Drive Demand for API and Spur Market Growth

The upsurge in occurrence of numerous communicable diseases and chronic health problems across the world is anticipated to fuel the demand for active pharmaceutical ingredients for the formulation of novel drugs.

Moreover, the increase in per head healthcare spending in the developing nations, along with the rise in diagnostic rates in these nations is giving rise to a huge population demanding treatment. This is further expected to amplify the demand for pharmaceutical drugs in the international market.

Inventive Product Launches by Crucial Players to Thrust Market Growth

The important players have used numerous tactics to thrust their position in the market as dominating companies. One such crucial approach is acquiring companies to drive the brand value among users. Another indispensable strategy is occasionally launching innovative products with comprehensive study of the market and its target audience.

Key Industry Development

• April 2020: Biocon announced the investment of USD 100.0 million in a new fermentation-based production facility for drug substances and intermediates.

List of Key Players Covered in the Report

• Teva Pharmaceutical Industries Ltd (Petah Tikva, Israel)


• AbbVie Inc. (North Chicago, U.S.)


• Abbott (Abbott Park, U.S.)


• Aurobindo Pharma (Hyderabad, India)


• Cipla Inc. (Mumbai, India)


• Dr. Reddy’s Laboratories Ltd (Hyderabad, India)


• Sun Pharmaceutical Industries Ltd (Mumbai, India)


• Amgen Inc. (Thousand Oaks, U.S.)


• Biocon (Bengaluru, India)


• Mylan N.V. (Canonsburg, U.S.)


• Boehringer Ingelheim International GmbH (Ingelheim am Rhein, Germany)

Further Findings

• Based on synthesis, the market is divided into synthetic and biological. The market is led by synthetic API segment, this is owing to the low production price of chemically manufactured API and moderately low cost of the raw materials utilized for the production of synthetic active pharmaceutical ingredients.


• North America was worth USD 76.77 billion in 2020 and the region is anticipated to be responsible for holding the highest active pharmaceutical ingredient market share of the global market during the predicted period.

Table of Segmentation